Former KL2 Scholar Receives METAvivor Research Award
Read about Dr. Matthew Cherian's research
Mathew Cherian, MBBS, assistant professor of Internal Medicine and medical oncologist who specializes in the treatment of breast cancer, received a METAvivor Research Award to fund his research to help treat metastatic breast cancer. Dr. Cherian’s work aims to determine the potential of a new class of drugs called sulfatase 2 inhibitors to treat metastatic triple-negative breast cancer, prolong patient survival and improve their quality of life.
METAvivor's research mission is twofold: to increase awareness about the funding discrepancy that shortchanges metastatic research in the cancer world, and to directly fund the metastatic research. METAvivor awards grants for research projects that have the potential to shift metastatic breast cancer from a terminal disease to a chronic condition people can live with. Dr. Cherian’s grant from METAvivor will further propel his research around design of therapies to improve outcomes of those with metastatic breast cancer.
Dr. Cherian was a KL2 scholar at the Center for Clinical and Translational Science (CCTS) from June 2019 to May 2022. The KL2 program supports the career development of investigators who have made a commitment to conduct either patient-oriented or translational research. To date, the CCTS has helped fund 40 investigators through the KL2 program since 2009 as they develop successful clinical and translational science careers.